|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRD5A1 |
Gene summary for SRD5A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRD5A1 | Gene ID | 6715 |
| Gene name | steroid 5 alpha-reductase 1 | |
| Gene Alias | S5AR 1 | |
| Cytomap | 5p15.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P18405 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6715 | SRD5A1 | HCC1_Meng | Human | Liver | HCC | 1.82e-15 | -1.07e-01 | 0.0246 |
| 6715 | SRD5A1 | HCC2_Meng | Human | Liver | HCC | 3.89e-06 | -8.37e-02 | 0.0107 |
| 6715 | SRD5A1 | HCC2 | Human | Liver | HCC | 1.11e-03 | 2.29e+00 | 0.5341 |
| 6715 | SRD5A1 | Pt13.b | Human | Liver | HCC | 1.19e-02 | -2.07e-02 | 0.0251 |
| 6715 | SRD5A1 | Pt14.d | Human | Liver | HCC | 3.96e-02 | -1.21e-01 | 0.0143 |
| 6715 | SRD5A1 | S014 | Human | Liver | HCC | 1.32e-08 | 4.02e-01 | 0.2254 |
| 6715 | SRD5A1 | S015 | Human | Liver | HCC | 6.44e-12 | 6.51e-01 | 0.2375 |
| 6715 | SRD5A1 | S016 | Human | Liver | HCC | 1.62e-10 | 5.10e-01 | 0.2243 |
| 6715 | SRD5A1 | S027 | Human | Liver | HCC | 3.53e-05 | 4.64e-01 | 0.2446 |
| 6715 | SRD5A1 | S028 | Human | Liver | HCC | 1.41e-18 | 6.40e-01 | 0.2503 |
| 6715 | SRD5A1 | S029 | Human | Liver | HCC | 1.85e-10 | 6.12e-01 | 0.2581 |
| 6715 | SRD5A1 | C04 | Human | Oral cavity | OSCC | 2.09e-21 | 7.96e-01 | 0.2633 |
| 6715 | SRD5A1 | C21 | Human | Oral cavity | OSCC | 3.78e-34 | 7.63e-01 | 0.2678 |
| 6715 | SRD5A1 | C30 | Human | Oral cavity | OSCC | 6.23e-43 | 1.45e+00 | 0.3055 |
| 6715 | SRD5A1 | C38 | Human | Oral cavity | OSCC | 6.03e-13 | 9.64e-01 | 0.172 |
| 6715 | SRD5A1 | C43 | Human | Oral cavity | OSCC | 1.82e-59 | 1.10e+00 | 0.1704 |
| 6715 | SRD5A1 | C46 | Human | Oral cavity | OSCC | 7.66e-76 | 1.46e+00 | 0.1673 |
| 6715 | SRD5A1 | C51 | Human | Oral cavity | OSCC | 1.82e-13 | 5.51e-01 | 0.2674 |
| 6715 | SRD5A1 | C57 | Human | Oral cavity | OSCC | 1.08e-10 | 3.64e-01 | 0.1679 |
| 6715 | SRD5A1 | C06 | Human | Oral cavity | OSCC | 1.74e-14 | 1.15e+00 | 0.2699 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
| GO:0022900110 | Esophagus | ESCC | electron transport chain | 133/8552 | 175/18723 | 2.18e-16 | 1.67e-14 | 133 |
| GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
| GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:0009267110 | Esophagus | ESCC | cellular response to starvation | 110/8552 | 156/18723 | 2.63e-10 | 7.37e-09 | 110 |
| GO:004259419 | Esophagus | ESCC | response to starvation | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
| GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
| GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
| GO:0061008110 | Esophagus | ESCC | hepaticobiliary system development | 98/8552 | 150/18723 | 8.91e-07 | 1.15e-05 | 98 |
| GO:0001889110 | Esophagus | ESCC | liver development | 96/8552 | 147/18723 | 1.18e-06 | 1.47e-05 | 96 |
| GO:0071383110 | Esophagus | ESCC | cellular response to steroid hormone stimulus | 127/8552 | 204/18723 | 1.26e-06 | 1.55e-05 | 127 |
| GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
| GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
| GO:003286918 | Esophagus | ESCC | cellular response to insulin stimulus | 124/8552 | 203/18723 | 6.63e-06 | 6.75e-05 | 124 |
| GO:003286818 | Esophagus | ESCC | response to insulin | 156/8552 | 264/18723 | 7.21e-06 | 7.20e-05 | 156 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRD5A1 | SNV | Missense_Mutation | c.460N>C | p.Gly154Arg | p.G154R | P18405 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SRD5A1 | SNV | Missense_Mutation | c.688N>C | p.Ser230Pro | p.S230P | P18405 | protein_coding | tolerated(0.2) | benign(0.145) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| SRD5A1 | SNV | Missense_Mutation | novel | c.408N>A | p.Ser136Arg | p.S136R | P18405 | protein_coding | deleterious(0.01) | possibly_damaging(0.463) | TCGA-AA-3869-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
| SRD5A1 | SNV | Missense_Mutation | c.353C>T | p.Thr118Ile | p.T118I | P18405 | protein_coding | tolerated(0.29) | benign(0) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| SRD5A1 | SNV | Missense_Mutation | c.613N>A | p.Glu205Lys | p.E205K | P18405 | protein_coding | deleterious(0.02) | possibly_damaging(0.856) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SRD5A1 | SNV | Missense_Mutation | novel | c.721N>T | p.Leu241Phe | p.L241F | P18405 | protein_coding | deleterious(0.02) | probably_damaging(0.917) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SRD5A1 | SNV | Missense_Mutation | c.758N>G | p.Ile253Ser | p.I253S | P18405 | protein_coding | tolerated(0.22) | benign(0.065) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SRD5A1 | SNV | Missense_Mutation | rs374499334 | c.674N>T | p.Thr225Met | p.T225M | P18405 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SRD5A1 | SNV | Missense_Mutation | novel | c.759N>G | p.Ile253Met | p.I253M | P18405 | protein_coding | tolerated(0.06) | benign(0.222) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SRD5A1 | SNV | Missense_Mutation | novel | c.286G>T | p.Gly96Trp | p.G96W | P18405 | protein_coding | deleterious(0.03) | benign(0.014) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6715 | SRD5A1 | DRUGGABLE GENOME | LEVONORGESTREL | LEVONORGESTREL | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | DUTASTERIDE | DUTASTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | BEXLOSTERIDE | BEXLOSTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | FR-146687 | |||
| 6715 | SRD5A1 | DRUGGABLE GENOME | FINASTERIDE | FINASTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | LY-266111 | CHEMBL29166 | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | FINASTERIDE | FINASTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | DUTASTERIDE | DUTASTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | inhibitor | CHEMBL1200969 | DUTASTERIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |